Table 2:
Distribution and age- and sex-adjusted risk (Hazard Ratios and 95% Confidence Intervals) of 16-year incident hearing impairment by biomarker quintile
| Incident Hearing impairment | |||
|---|---|---|---|
| No N (%) | Yes N (%) | HR (95%CI)† | |
| Aldosterone (ng/dL) | |||
| Q1 (<5.03) | 107 (21.8) | 135 (22.6) | 1.06 (0.82, 1.37) |
| Q2 (5.03–6.96) | 106 (21.6) | 122 (20.5) | 0.91 (0.70, 1.18) |
| Q3 (6.97–9.27) | 95 (19.4) | 109 (18.3) | 0.82 (0.63, 1.07) |
| Q4 (9.28–12.3) | 99 (20.2) | 113 (19.0) | 0.95 (0.73, 1.23) |
| Q5 (12.4+) | 83 (16.9) | 117 (19.6) | Reference |
| IGF1 (ng/mL) | |||
| Q1 (<54.05) | 96 (19.5) | 125 (20.9) | 0.92 (0.71, 1.19) |
| Q2 (54.05–66.31) | 111 (22.6) | 98 (16.4) | 0.66 (0.50, 0.86) |
| Q3 (66.32–77.76) | 107 (21.8) | 133 (22.3) | 0.87 (0.68, 1.11) |
| Q4 (77.77–93.56) | 98 (20.0) | 116 (19.4) | 0.80 (0.62, 1.04) |
| Q5 (93.57+) | 79 (16.1) | 125 (20.9) | Reference |
| BDNF (ng/mL) | |||
| Q1 (<15.80) | 77 (15.7) | 104 (17.4) | 0.86 (0.66, 1.12) |
| Q2 (15.81–19.27) | 91 (18.5) | 126 (21.1) | 1.06 (0.83, 1.36) |
| Q3 (19.28–22.43) | 99 (20.2) | 122 (20.4) | 0.94 (0.73, 1.21) |
| Q4 (22.44–25.99) | 117 (23.8) | 110 (18.4) | 0.72 (0.55, 0.93) |
| Q5 (26.00+) | 107 (21.8) | 135 (22.6) | Reference |
†
Adjusted for age and sex